NEWLINK GENETICS CORP Business Operations Contracts & Agreements

39 Contracts & Agreements
Browse by Subcategory
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Amendment to License and Collaboration Agreement dated
Collaboration Agreements
NEWLINK GENETICS CORP
Biotechnology
2019
Amendment No. 3 to License and Collaboration Agreement by and between the Registrant and Merck Sharp & Dohme Corp., dated October 9, 2018
Collaboration Agreements
NEWLINK GENETICS CORP
Biotechnology
2018
Amendment to License and Collaboration Agreement by and between Merck Sharp & Dohme Corp., dated May 10, 2018
Collaboration Agreements
NEWLINK GENETICS CORP
Biotechnology
2018
Controlled Equity OfferingSM Sales Agreement, dated March 12, 2018, by and between NewLink Genetics Corporation and Cantor Fitzgerald & Co
Sales Agreements
NEWLINK GENETICS CORP
Biotechnology
NY
2018
Amendment to License and Collaboration Agreement dated December 5, 2017 by and among the Company, BioProtection Systems Corporation and Merck Sharp & Dohme Corp
Collaboration Agreements
NEWLINK GENETICS CORP
Biotechnology
2018
RESEARCH SERVICES AGREEMENT
Services Agreements
NEWLINK GENETICS CORP
Biotechnology
2016
FIRST AMENDED AND RESTATED CELL THERAPY DEVELOPMENT, MANUFACTURING AND/OR TISSUE PROCESSING TERMS AND CONDITIONS BETWEEN WuXi AppTec, Inc. and NewLink Genetics Corporation
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
NY
2016
FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN NEWLINK GENETICS CORPORATION, NEWLINK GLOBAL, GENENTECH, INC. AND F. HOFFMANN-LA ROCHE LTD OF OCTOBER 16,...
Collaboration Agreements
NEWLINK GENETICS CORP
Biotechnology
2015
LICENSE AND COLLABORATION AGREEMENT
Collaboration Agreements
NEWLINK GENETICS CORP
Biotechnology
NY
2015
Amendment to Development and Manufacturing Terms and Conditions
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
NY
2014
License and Collaboration Agreement by and between NewLink Genetics Corporation and NewLink Global and Genentech, Inc. and F. Hoffmann-La Roche Ltd October 16, 2014
Collaboration Agreements
NEWLINK GENETICS CORP
Biotechnology
NY
2014
Development and Process Transfer Program Leading to Commercial Manufacturing for algenpantucel-L HyperAcute" Pancreas Technical Transfer, Verification / Process Development,...
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2014
CELL THERAPY DEVELOPMENT, MANUFACTURING AND/OR TISSUE PROCESSING TERMS AND CONDITIONS BETWEEN WuXi AppTec, Inc. and NewLink Genetics Corporation
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
NY
2014
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCH
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
DC
2012
SETTLEMENT AGREEMENT
Settlement Agreements
NEWLINK GENETICS CORP
Biotechnology
IA
2012
HER MAJESTY THE QUEEN IN RIGHT OF CANADA, as represented by the Minister of Health, acting through the Public Health Agency of Canada (Canada)
Agency Agreements
NEWLINK GENETICS CORP
Biotechnology
IA
2011
AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #8 To Letter of Intent for Proposed CRADA #02166 Preclinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
HER MAJESTY THE QUEEN IN RIGHT OF CANADA, as represented by the Minister of Health, acting through the Public Health Agency of Canada (Canada)
Agency Agreements
NEWLINK GENETICS CORP
Biotechnology
IA
2011
AMENDMENT #7 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #6 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #5 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #4 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #3 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER RESEARCH TRIANGLE PARK DIVISION P.O. BOX 12211 RESEARCH TRIANGLE PARK, NORTH...
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #7 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
$6,000,000 IOWA VALUES FUND (IVF) CONTRACT BY AND BETWEEN NEWLINK GENETICS CORPORATION AND THE IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT DATED AS OF MARCH 18, 2005
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
IA
2010
AMENDMENT #6 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
AMENDMENT #5 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
AMENDMENT #4 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
AMENDMENT #3 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
Cooperative Research and Development Agreement (CRADA #1901) [*] NCI Principal Investigator John C. Morris, M.D. Metabolism Branch, CCR, NCI Collaborator PrincipalInvestigator...
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
DC
2010